Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. META

Go back to Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals (ACAD) PT Lowered to $26 at RBC Capital

August 7, 2024 6:24 AM EDT

RBC Capital analyst Gregory Renza lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $29.00) while maintaining a Outperform rating.

The analyst comments "Daybue miss representative of launch growing pains, in our view, as new patient starts fall short of Street (and even... More